D
Do Young Kim
Researcher at Yonsei University
Publications - 737
Citations - 18320
Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Community-acquired vs. nosocomial spontaneous bacterial peritonitis in patients with liver cirrhosis.
Young Eun Chon,Seung Up Kim,Chun Kyon Lee,Jun Yong Park,Do Young Kim,Kwang Hyub Han,Chae Yoon Chon,Sinyoung Kim,Kyu Sik Jung,Sang Hoon Ahn +9 more
TL;DR: N-SBP was significantly associated with increased antibiotic switching, higher in-hospital mortality and shorter overall survival, and third-generation cephalosporin may be inappropriate as first-line empirical antibiotics for patients with N- SBP.
Journal ArticleDOI
Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
Tae Seop Lim,Hyungjin Rhee,Gyoung Min Kim,Seung Up Kim,Beom Kyung Kim,Jun Yong Park,Sang Hoon Ahn,Kwang Hyub Han,Jin-Young Choi,Do Young Kim +9 more
TL;DR: AFP, DCP, and mRECIST responders showed better prognosis than nonresponders after TARE, and DCP response was a more potent predictor than AFP response.
Journal ArticleDOI
Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
Eun Jin Yoo,Hye Sun Shin,Seung Up Kim,Dong Jin Joo,Jun Yong Park,Gi Hong Choi,Do Young Kim,Sang Hoon Ahn,Jinsil Seong,Myung Joo Koh,Kwang Hyub Han,Chae Yoon Chon +11 more
TL;DR: A remarkable decrease in the tumor burden that satisfied the University of California, San Francisco criteria was observed after these combination treatments and the patient underwent orthotopic liver transplantation with curative aim and survived for 11 months without evidence of HCC recurrence.
Journal ArticleDOI
Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study.
TL;DR: For the past 12 years, curative treatments became more widely available to BCLC 0~A, B, and C stage patients, generally improving prognosis and despite sorafenib reimbursement, LRTs remain the mainstay of first-line treatment for B CLC C stage Patients.
Journal ArticleDOI
Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B
Mi Sung Park,Beom Kyung Kim,Jae Yoeun Cheong,Dong Joon Kim,Jun Yong Park,Do Young Kim,Sang Hoon Ahn,Kwang Hyub Han,Chae Yoon Chon,Seung Up Kim +9 more
TL;DR: Advanced fibrosis stage (F3–4) is the sole factor of discordance between FT and LB in Asian patients with CHB, and neither necroinflammatory activity on histology nor serum ALT level influenced FT values independently.